Anxiety SOAP Note Example (GAD, Panic & Social Anxiety)
Dr. Medeline Yost
Chief Medical Officer, Augustun
Published July 11, 2026
Updated July 11, 2026
On this page
- Why Vague Anxiety Notes Fail
- GAD vs Panic vs Social Anxiety — What to Emphasize
- GAD-7 and Other Scales in Anxiety Notes
- Therapy Visit vs Medication-Management Visit
- Anxiety SOAP Note Template
- Anxiety SOAP Note Examples
- Benzodiazepine Documentation Caveats
- Common Mistakes in Anxiety SOAP Notes
- Let Augustun Draft Your Anxiety Notes
- Conclusion
- FAQ
Anxiety is one of the most common reasons patients present to psychiatry and therapy — and one of the easiest presentations to under-document. A note that only says the patient is anxious tells the next clinician almost nothing about severity, triggers, avoidance, or why today's plan is medically necessary.
A strong anxiety SOAP note captures what the worry looks like in the body and in daily life: somatic symptoms, panic frequency, situations avoided, and how those symptoms change over time. Whether you are writing a CBT progress note or a medication follow-up, the same structure keeps your reasoning clear and audit-ready.
This guide focuses on anxiety documentation specifically. For the full psychiatric SOAP framework — MSE placement, risk formulation, and general psych examples — start with our psychiatric SOAP note hub. Below you will find diagnosis-specific documentation focus, rating-scale guidance, a fillable template, and four complete anxiety SOAP note examples spanning GAD, panic, and social anxiety.
Why Vague Anxiety Notes Fail
Payers and auditors look for medical necessity. Writing that the 'patient is anxious' or 'reports anxiety' does not establish it. A reviewer cannot tell whether symptoms meet DSM-5 criteria, whether functioning is impaired, or whether your intervention matches the clinical picture.
Anxiety documentation needs four concrete elements every visit:
- Triggers — situations, thoughts, or times of day that worsen worry or panic (e.g., work deadlines, driving, social meals, health-related cues)
- Somatic symptoms — muscle tension, restlessness, palpitations, shortness of breath, GI distress, tremor, sweating, dizziness — named and timed when possible
- Avoidance — what the patient skips, truncates, or relies on others to do; include safety behaviors (checking, reassurance-seeking, leaving early)
- Frequency and duration — how often panic attacks occur, how many hours of worry per day, how long symptoms have been present, and change since last visit
Pair those details with a rating scale (usually GAD-7) and a brief functional statement — missed work, delayed sleep, avoided meetings — and your note supports both clinical continuity and billing.
Quote the impact, not just the label
Patient language that shows impairment is stronger than a severity adjective. Prefer 'I canceled two client calls because I couldn't stop shaking' over 'severe anxiety.' Keep quotes in the Subjective; keep your clinical labels for Assessment.
GAD vs Panic vs Social Anxiety — What to Emphasize
All three conditions involve fear and avoidance, but the documentation focus differs. Use this table to keep Subjective and Assessment aligned with the working diagnosis.
| Focus | GAD (F41.1) | Panic Disorder (F41.0) | Social Anxiety (F40.10) |
|---|---|---|---|
| Core Subjective content | Excessive worry across domains; hard to control; restlessness, fatigue, irritability, muscle tension, sleep disturbance | Unexpected panic attacks; fear of next attack; avoidance of places where escape feels hard | Fear of scrutiny, embarrassment, or negative evaluation; anticipatory anxiety before social/performance situations |
| Key details to quantify | Hours of worry/day; number of worry domains; sleep onset latency; concentration impact | Attack frequency (e.g., 3/week); peak symptoms; duration; inter-attack worry; ER visits or medical workups | Feared situations list; avoidance hierarchy; safety behaviors; occupational/school impact |
| Objective / MSE cues | Tense posture, fidgeting, pressured worry when discussing stressors; GAD-7 | Autonomic signs if mid-attack or residual; hypervigilance to bodily sensations; panic-related scales if used | Avoidant eye contact in session, soft speech, visible distress discussing social scenarios; LSAS or SPIN if used |
| Assessment emphasis | DSM-5 GAD criteria; rule out substance/medical; distinguish from panic and OCD | Recurrent unexpected attacks + concern/behavior change; rule out cardiac/thyroid/substance; agoraphobia specifier | Markedly out of proportion fear; avoidance or endurance with intense distress; not better explained by another disorder |
| Plan hooks | CBT (worry exposure, worry time), SSRIs/SNRIs, sleep hygiene, limit caffeine | Psychoeducation on panic cycle, interoceptive exposure, SSRIs, cautious benzo use if any | Exposure hierarchy, cognitive restructuring, social skills if indicated, SSRI if moderate–severe |
Comorbidity is common — GAD with panic attacks, social anxiety with depression — so document the primary driver of today's visit and name co-occurring conditions explicitly rather than collapsing everything into 'anxiety.'
GAD-7 and Other Scales in Anxiety Notes
Standardized scales make progress visible and support medical necessity. Record the score, the interpretation band, and the comparison to prior visits.
- GAD-7 — primary screen for generalized anxiety; 0–4 minimal, 5–9 mild, 10–14 moderate, 15–21 severe. Document total and, when useful, highest-scoring items (e.g., sleep, restlessness).
- PHQ-9 — anxiety and depression frequently co-travel; include when mood symptoms are present or for differential.
- Panic Disorder Severity Scale (PDSS) or brief panic frequency/intensity counts when panic is the focus.
- Liebowitz Social Anxiety Scale (LSAS) or SPIN for social anxiety when you need severity trending beyond clinical description.
- PCL-5 — if trauma-related anxiety is on the differential; do not attribute trauma symptoms solely to GAD.
Example phrasing: 'GAD-7 = 16 (severe), down from 19 four weeks ago — modest improvement; sleep and restlessness items remain elevated. Functionally, patient returned to one in-person meeting per week.'
Therapy Visit vs Medication-Management Visit
Both visit types can use SOAP, but the weight of each section shifts.
| Section | Therapy / CBT progress note | Med-management visit |
|---|---|---|
| Subjective | Homework adherence, exposure attempts, cognitive themes, between-session anxiety spikes | Symptom course on meds, side effects, adherence, substance use, sleep, residual worry/panic |
| Objective | Affect and engagement in session, behavioral observations during exposure discussion, scale scores | MSE, vitals if relevant, scale scores, abnormal movements if on antipsychotics (less common in pure anxiety regimens) |
| Assessment | Response to interventions used today; skill acquisition; remaining hierarchy items; diagnosis update | Diagnostic stability, medication response/partial response, side-effect burden, risk, medical necessity for continued Rx |
| Plan | Next exposures, homework, session frequency, coordination with prescriber | Continue/adjust/stop meds with rationale, labs if indicated, therapy referral, follow-up interval, safety plan |
If you provide both therapy and medication in one encounter, document both threads so a reviewer can see what was psychotherapeutic versus pharmacologic. For alternative structures used in counseling, see our guide to BIRP notes for mental health.
Anxiety SOAP Note Template
Copy this skeleton for GAD, panic, or social anxiety visits. Trim sections that do not apply; never leave Assessment or risk blank.
Anxiety SOAP Note — Template
- S (Subjective)
- Chief complaint in the patient's words. Anxiety course since last visit: worry domains or panic frequency, triggers, somatic symptoms, avoidance and safety behaviors, sleep, substances/caffeine. Functional impact (work, school, relationships). Medication adherence and side effects if applicable. Therapy homework / exposure practice. Direct quotes showing impairment. SI/HI screen in patient's words.
- O (Objective) — Mental Status Exam
- Appearance, behavior (tension, fidgeting, avoidance of eye contact), speech, mood (patient's words) and affect, thought process/content (catastrophic themes, obsessions if present), perception, cognition/orientation, insight and judgment. GAD-7 (and PHQ-9 or other scales as indicated). Vitals if relevant to panic or med monitoring.
- A (Assessment)
- Working diagnosis with ICD-10 (e.g., GAD F41.1, panic disorder F41.0, social anxiety F40.10) and supporting DSM-5 criteria. Specifiers and comorbidity. Severity and change since last visit tied to scales and function. Differentials ruled out or pending. Explicit suicide/homicide risk formulation with risk and protective factors.
- P (Plan)
- Therapy interventions and homework, or medication start/continue/adjust with rationale. Benzodiazepine status if prescribed (indication, duration limits, risks discussed, alternatives). Sleep and lifestyle counseling. Safety plan / crisis resources. Follow-up interval and what will be re-measured (GAD-7, panic count, exposure hierarchy progress).
Anxiety SOAP Note Examples
Four complete examples follow. Names and details are illustrative. Adapt structure and phrasing to your patient — do not copy diagnoses without clinical criteria.
Example 1 — GAD: CBT Progress Note
Priya is a 34-year-old project manager in weekly CBT for generalized anxiety. This note emphasizes homework, cognitive themes, and measurable change.
Anxiety SOAP Note — GAD CBT Progress
- S (Subjective)
- 34-year-old female returns for session 6 of CBT for GAD. Reports worry remains 'most of the day' about work quality and family health, but she completed worry-time practice 5/7 days. States, 'I still spiral at 2 a.m., but I wrote the worries down instead of checking my email.' Muscle tension and jaw clenching daily; sleep-onset latency ~45 minutes (was 90). Avoided one team presentation by asking a colleague to present; completed two smaller status updates in person. Caffeine reduced to one coffee. Denies panic attacks. Denies SI/HI.
- O (Objective)
- Well-groomed, sits forward on chair, intermittent foot tapping. Speech normal rate. Mood 'wired but trying'; affect anxious, congruent, reactive. Thought process logical with catastrophic 'what if' themes when discussing work; no delusions. No perceptual disturbance. Oriented x3; concentration mildly reduced when discussing upcoming deadlines. Insight good; judgment intact. GAD-7 = 14 (moderate; prior visit 17). PHQ-9 = 6.
- A (Assessment)
- Generalized Anxiety Disorder (F41.1), moderate, with partial response to CBT — GAD-7 down 3 points, sleep onset improved, worry-time adherence good; residual excessive worry, muscle tension, and one instance of presentation avoidance. Meets DSM-5 GAD criteria (excessive worry >6 months, difficulty controlling worry, restlessness/tension/sleep disturbance, functional impairment). R/O panic disorder — no unexpected panic attacks. Suicide risk: denies ideation, plan, intent; protective factors include treatment engagement and occupational motivation — low acute risk.
- P (Plan)
- Continue weekly CBT. Homework: scheduled worry time 15 min nightly; behavioral experiment for next status meeting (remain 10 minutes after speaking); progressive muscle relaxation nightly. Reviewed cognitive distortion of fortune-telling. Coordinated with PCP/psychiatry — patient not on anxiolytic meds currently; will reconsider SSRI referral if GAD-7 remains ≥10 after 4 more sessions. Safety resources reviewed. Follow-up in 1 week with repeat GAD-7.
Example 2 — Panic Disorder: Medication Follow-Up
Marcus is a 41-year-old returning for med management after starting sertraline for panic disorder. Focus on attack frequency, inter-attack worry, and medication rationale.
Anxiety SOAP Note — Panic Disorder Med Follow-Up
- S (Subjective)
- 41-year-old male with panic disorder returns 4 weeks after starting sertraline. Panic attacks decreased from ~4/week to 1–2/week. Last attack 3 days ago: sudden palpitations, shortness of breath, dizziness, fear of 'dying or going crazy,' peaked in ~10 minutes while grocery shopping. States, 'I'm still scared it'll happen in the car, so I've been taking the back roads.' Continues to avoid highways and large stores some days. Sleep improved slightly. Sertraline 50 mg daily; mild nausea week 1, now resolved. No missed doses. Denies alcohol bingeing; caffeine 2 cups/day. Denies SI/HI. No benzo use this month.
- O (Objective)
- Casually dressed, mild psychomotor tension. Speech normal. Mood 'on edge'; affect anxious but appropriate. Thought process linear; thought content notable for health-related catastrophic interpretations during attacks, no delusions. No hallucinations. Oriented x3, cognition intact. Insight good; judgment intact. GAD-7 = 12. BP 132/84, HR 86. No tremor.
- A (Assessment)
- Panic disorder (F41.0), with agoraphobic features (highway and large-store avoidance), partial response to sertraline 50 mg — attack frequency reduced but still clinically significant; anticipatory anxiety and avoidance persist. Meets DSM-5 criteria for recurrent unexpected panic attacks with persistent concern and maladaptive behavior change. Medical workup previously negative per patient (ECG, TSH). Suicide risk: denies ideation — low risk. Benefits of continued pharmacotherapy outweigh risks; dose may be suboptimal for residual symptoms.
- P (Plan)
- Increase sertraline from 50 mg to 100 mg daily for residual panic and avoidance; discussed delayed therapeutic effect, possible transient activation, sexual side effects, and serotonin syndrome precautions. No benzodiazepine prescribed today — reviewed risks of dependence and interference with exposure learning; offered PRN hydroxyzine 25 mg as alternative if acute distress, patient declined. Referral to CBT with interoceptive and in-vivo exposure. Limit caffeine. Return precautions for chest pain with new neurologic features. Follow-up in 3 weeks; track panic frequency and GAD-7.
Example 3 — Social Anxiety: Exposure Work
Elena is a 27-year-old graduate student in exposure-based CBT for social anxiety. The note tracks hierarchy progress and safety behaviors.
Anxiety SOAP Note — Social Anxiety Exposure
- S (Subjective)
- 27-year-old female returns for session 8 of exposure-based CBT for social anxiety. Hierarchy item this week: ask a clarifying question in seminar (SUDS peak 70 → 40 by end of class). Completed 2 of 3 planned exposures; skipped one networking event, stating, 'I practiced my opener but left when I saw how many people were there.' Still uses phone as safety behavior in hallways. Blushing and voice tremor remain main feared outcomes. Anticipatory anxiety the night before class interferes with sleep (~5 hours). Denies panic attacks outside social cues. Denies SI/HI. Not on psychiatric medication.
- O (Objective)
- Appropriately dressed, limited eye contact at start of session, improves with rapport. Soft speech initially, volume normalizes. Mood 'embarrassed I bailed'; affect anxious, tearful briefly when discussing skipped event, then recovers. Thought process goal-directed; content focused on feared negative evaluation. No psychosis. Oriented x3. Insight good; judgment intact. GAD-7 = 11. SPIN = 38 (prior 44).
- A (Assessment)
- Social anxiety disorder (social phobia) (F40.10), moderate, with early response to exposure therapy — SPIN improved 6 points; successful in-seminar exposure with SUDS decrease; residual avoidance (networking event) and safety behaviors (phone use). Fear is out of proportion and causes academic impairment. Differentials: GAD less likely as primary — worry is predominantly social-evaluative; ASD traits not suggested. Suicide risk: denies — low risk.
- P (Plan)
- Continue weekly exposure CBT. Homework: (1) one clarifying question in next seminar without rehearsing more than once; (2) 10-minute hallway conversation without phone; (3) drop safety behavior of apologizing pre-emptively. Reviewed drop-out of networking event as avoidance maintaining cycle; planned graded alternative (arrive with one classmate, stay 20 minutes). Discussed SSRI option if progress stalls after 4 more sessions; patient prefers therapy-first approach. Follow-up in 1 week with SUDS log and repeat SPIN in 4 weeks.
Example 4 — GAD with Insomnia: Medication Management
James is a 52-year-old with GAD and chronic insomnia on escitalopram, seen for med management. Sleep and benzo stewardship are central.
Anxiety SOAP Note — GAD with Insomnia Med Management
- S (Subjective)
- 52-year-old male with GAD and insomnia returns for 6-week follow-up. Worry about finances and adult children's safety remains 'constant in the background' but less intense than intake. States, 'I still wake at 3 a.m. and start problem-solving until I give up.' Sleep: latency 30–40 min; total sleep ~5.5 hours; uses phone in bed. Escitalopram 10 mg daily, adherent; no sexual side effects reported. Previously used lorazepam 0.5 mg PRN 'a few nights a week' — reports 8 tablets used in past month (within prior limit). Requests refill. Daytime fatigue and irritability. Caffeine until 3 p.m. Denies SI/HI. Weekly therapy inconsistently attended (2 of last 4 sessions).
- O (Objective)
- Tired appearance, rubs neck frequently. Speech normal. Mood 'exhausted and tense'; affect constricted-anxious. Thought process linear; no hopelessness themes beyond financial worry. No perceptual disturbance. Oriented x3; attention mildly reduced. Insight fair; judgment intact. GAD-7 = 13 (intake 18). PHQ-9 = 8 (sleep and energy items elevated). BP 138/86, HR 78.
- A (Assessment)
- 1) Generalized Anxiety Disorder (F41.1), mild–moderate, partial response to escitalopram 10 mg — GAD-7 improved but still above remission. 2) Insomnia disorder, comorbid — residual middle insomnia with nocturnal worry, behavioral contributors (phone in bed, late caffeine). Benzodiazepine use: intermittent lorazepam within prescribed limits but ongoing need suggests incomplete control of nocturnal anxiety and risk of reinforcing insomnia if continued long-term. Suicide risk: denies ideation — low risk. Dose optimization and non-benzo sleep strategy indicated.
- P (Plan)
- Increase escitalopram to 15 mg daily for residual GAD; counsel on transient side effects. Lorazepam 0.5 mg: renew limited quantity (#10 tablets, no refill) with explicit time-limited plan — not for nightly use; discuss dependence, falls, cognitive risk, and interference with CBT-I. Alternatives reviewed: sleep restriction / stimulus control referral to CBT-I; consider low-dose trazodone or hydroxyzine if non-benzo pharmacologic sleep aid needed at next visit; melatonin discussed, patient to trial 1–3 mg. Sleep hygiene: no screens in bed, caffeine cutoff noon. Encourage consistent therapy attendance. Follow-up in 4 weeks with GAD-7 and sleep diary; sooner if insomnia worsens or mood declines.
Benzodiazepine Documentation Caveats
Benzodiazepines still appear in anxiety care plans, but the chart must show that you weighed risk against benefit. Incomplete benzo documentation is a common audit and liability problem.
- Indication and target symptoms — panic surge, short-term bridge while SSRI starts, procedure-related anxiety — not a vague 'for anxiety.'
- Duration and quantity limits — expected length of use, tablet count, no early refills without reassessment.
- Risks discussed — dependence, tolerance, withdrawal, sedation, falls (especially older adults), driving impairment, overdose risk with opioids/alcohol.
- Alternatives offered — SSRIs/SNRIs, hydroxyzine, propranolol for performance anxiety when appropriate, CBT/exposure, sleep-focused therapy for nocturnal anxiety.
- Monitoring — pill counts or PDMP when indicated, substance use screen, plan to taper when clinically appropriate.
If you continue a benzo, say why the benefits still outweigh risks for this patient at this visit. If you decline a refill request, document the clinical rationale and the alternative plan you offered — as in Example 4.
Exposure and benzos
When the treatment plan includes exposure therapy, note whether PRN benzos might blunt learning. Many clinicians document a shared decision to minimize PRN use on exposure days.
Common Mistakes in Anxiety SOAP Notes
Collapsing all anxiety into one label
Panic, GAD, and social anxiety have different interventions. If the visit is about highway avoidance after unexpected attacks, name panic disorder (and agoraphobia if present) rather than only 'anxiety.'
Skipping avoidance and safety behaviors
Severity lives in what the patient no longer does. Document canceled events, escape behaviors, reassurance calls, and checking — then tie the Plan to reducing them.
Scale without context
GAD-7 = 14 means more when you add the prior score and a functional anchor. Always trend and interpret.
Plan that ignores the assessment
If Assessment notes ongoing panic and avoidance but Plan only says 'continue meds, RTC 3 months,' reviewers cannot see your reasoning. Match interval and interventions to residual severity.
Missing risk screen
Anxiety notes still need explicit SI/HI documentation every visit. A documented negative protects you; silence does not.
Benzo refill without stewardship language
Refilling lorazepam 'as before' without risks, limits, or alternatives discussed leaves a gap. Write the conversation.
Let Augustun Draft Your Anxiety Notes
Anxiety visits move quickly — patients describe cascades of worry, panic cues, and avoidance while you are also tracking scales, meds, and risk. Augustun for psychiatry listens during the encounter and drafts a structured SOAP note with mental status, scale placeholders, ICD-10 suggestions, and a plan you can edit and sign.
Augustun supports SOAP, DAP, and BIRP formats, works across therapy and med-management workflows, and connects to 400+ EHRs through a browser extension. It is built for clinical use with HIPAA compliance, and recordings are never stored.
AI-Powered · HIPAA-Ready
Spend the visit on exposure and nuance — not on typing
See how Augustun captures triggers, somatic symptoms, and plan details for psychiatry and therapy notes. Start a demo and keep your anxiety documentation specific enough for care and audit.
No credit card required.
Built for behavioral health detail
Whether you are documenting CBT homework, panic frequency, or a careful benzo discussion, Augustun drafts the structure so you can refine clinical judgment. For the broader psych documentation picture, see how to write psychiatry notes and our depression progress note guide.
Conclusion
Strong anxiety SOAP notes replace 'patient is anxious' with triggers, somatic symptoms, avoidance, frequency, and scales. Differentiate GAD, panic, and social anxiety in both Assessment and Plan; document therapy work and medication decisions with equal clarity; and treat benzodiazepines as high-scrutiny prescriptions that need indication, limits, risks, and alternatives on the record.
Use the template above, adapt one of the four examples to your next visit, and keep risk and functional impact explicit every time. Clear anxiety documentation protects continuity of care — and makes the next clinician's job easier.
Frequently asked questions
What should an anxiety SOAP note include?
Include the patient's description of worry or panic (with quotes when useful), triggers, somatic symptoms, avoidance and safety behaviors, frequency/duration, functional impact, MSE findings, a scale such as GAD-7, diagnosis with supporting criteria, explicit SI/HI screening, and a plan that matches residual severity — therapy steps, medication changes with rationale, and follow-up.
How do you document GAD vs panic disorder in a SOAP note?
For GAD, emphasize uncontrollable worry across domains, tension, sleep disturbance, and hours of worry. For panic disorder, quantify unexpected attack frequency, peak somatic symptoms, fear of dying/losing control, inter-attack worry, and avoidance of places where escape feels difficult. Use ICD-10 codes F41.1 vs F41.0 and name comorbidity when both are present.
Is GAD-7 enough for anxiety documentation?
GAD-7 is the workhorse screen for generalized anxiety and a useful trend measure, but it is not a complete note. Add clinical description, functional impact, diagnosis-specific details (panic counts, social avoidance), and other scales (PHQ-9, SPIN, PDSS) when the presentation calls for them.
How should benzodiazepines be documented in anxiety notes?
Document the specific indication, dose, quantity limits, expected duration, risks discussed (dependence, sedation, falls, interaction with alcohol/opioids), alternatives offered (SSRI, hydroxyzine, CBT/exposure, sleep therapy), and monitoring or taper plans. Avoid open-ended 'continue PRN benzo' language without stewardship detail.
Can an AI scribe write anxiety SOAP notes?
Yes. An ambient AI scribe like Augustun can draft a structured anxiety SOAP note from the visit — including subjective symptom detail, MSE, scale fields, and a plan — for you to review and sign. It supports common behavioral health formats, is HIPAA compliant, does not store recordings, and integrates with 400+ EHRs via browser extension.
AI-Powered · HIPAA-Ready
Spend more time with patients, not paperwork.
Augustun transforms ambient speech into accurate notes — finished before your next session.
No credit card required.

Dr. Medeline Yost
Chief Medical Officer, Augustun
Dr. Medeline Yost is an Internal Medicine physician and an emerging leader in clinical innovation. As Chief Medical Officer at Augustun, she helps shape AI-powered tools that streamline clinical documentation and support physicians in delivering higher-quality care. Her professional interests include medical education, workflow redesign, and the responsible use of AI in healthcare — building systems that let clinicians spend more time with patients and less on administrative tasks.